Evidence map›Paper›PMID 37246729›Full record

ArticleJournal of veterinary internal medicine

The T2-FLAIR mismatch sign as an imaging biomarker for oligodendrogliomas in dogs.

Josefa Garcia-Mora, Rell L Parker, Thomas Cecere, John L Robertson, John H Rossmeisl

Open access · goldAbstract read
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Josefa Garcia-MoraDepartment of Small Animal Clinical Sciences and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, USA.ORCID https://orcid.org/0000-0001-6284-6210
Rell L ParkerDepartment of Small Animal Clinical Sciences and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, USA.ORCID https://orcid.org/0000-0002-4538-1818
Thomas CecereDepartment of Biomedical Sciences & Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, USA.
John L RobertsonVeterinary and Comparative Neuro-Oncology Laboratory, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, USA.
John H RossmeislDepartment of Small Animal Clinical Sciences and Animal Cancer Care and Research Center, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, USA.ORCID https://orcid.org/0000-0003-1655-7076
Virginia–Maryland College of Veterinary Medicine · US

Funding

The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve HealthUL1TR003015 · NCATS · UNIVERSITY OF VIRGINIA · PI BROWN, DONALD E, JOHNSTON, KAREN C. · 2019 to 2023
$20.3M
Sub-component for Institution # 16-01848 Novel moleculary targeted therapy of GBMP01CA207206 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DAGOSTINO, RALPH B. · 2017 to 2021
$9.0M
Institutional Career Development CoreKL2TR003016 · NCATS · UNIVERSITY OF VIRGINIA · PI PAPIN, JASON, WORRALL, BRADFORD B · 2019 to 2023
$3.9M
Multi-receptor Targeting of GlioblastomaR01CA256285 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Waldemar Debinski · 2021 to 2026
$2.8M
High-frequency Irreversible Electroporation (H-FIRE) combinatorial GBM treatmentR01CA213423 · NCI · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI DAVALOS, RAFAEL VIDAL, VERBRIDGE, SCOTT S · 2017 to 2021
$1.7M
Molecular Combinatorial Therapy of Glioblastoma MultiformeR01CA139099 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DEBINSKI, WALDEMAR · 2010 to 2014
$1.5M
NCATS NIH HHS KL2 TR003016NCATS NIH HHS UL1 TR003015NCI NIH HHS P01 CA207206NCI NIH HHS R01 CA139099NCI NIH HHS R01 CA213423NCI NIH HHS R01 CA256285NIH HHS KL2TR003016NIH HHS P01CA207206NIH HHS R01CA139099NIH HHS R01CA213423NIH HHS R01CA256285NIH HHS UL1TR003015
6 · The paper itself

Abstract

backgroundIn humans, the T2-weighted (T2W)-fluid-attenuated inversion recovery (FLAIR) mismatch sign (T2FMM) is a specific imaging biomarker for the isocitrate dehydrogenase 1 (IDH1)-mutated, 1p/19q non-codeleted low-grade astrocytomas (LGA). The T2FMM is characterized by a homogeneous hyperintense T2W signal and a hypointense signal with a hyperintense peripheral rim on FLAIR sequences. In gliomas in dogs, the T2FMM has not been described. HYPOTHESES/

objectivesIn dogs with focal intra-axial brain lesions, T2FMM will discriminate gliomas from other lesions. The T2FMM will be associated with the LGA phenotype and presence of microcysts on histopathology. Interobserver agreement for T2FMM magnetic resonance imaging (MRI) features will be high. ANIMALS: One hundred eighty-six dogs with histopathologically diagnosed focal intra-axial lesions on brain MRI including oligodendrogliomas (n = 90), astrocytomas (n = 47), undefined gliomas (n = 9), cerebrovascular accidents (n = 33), and inflammatory lesions (n = 7).

methodsTwo blinded raters evaluated the 186 MRI studies and identified cases with the T2FMM. Histopathologic and immunohistochemical slides of T2FMM cases were evaluated for morphologic features and IDH1-mutations and compared to cases without the T2FMM. Gene expression analyses were performed on a subset of oligodendrogliomas (n = 10) with and without T2FMM.

resultsThe T2FMM was identified in 14/186 (8%) of MRI studies, and all dogs with T2FMM had oligodendrogliomas (n = 12 low-grade [LGO], n = 2 high-grade [HGO]; P < .001). Microcystic change was significantly associated with the T2FMM (P < .00001). In oligodendrogliomas with T2FMM, IDH1-mutations or specific differentially expressed genes were not identified. CONCLUSION AND CLINICAL IMPORTANCE: The T2FMM can be readily identified on routinely obtained MRI sequences. It is a specific biomarker for oligodendroglioma in dogs, and was significantly associated with non-enhancing LGO.

Indexed as

AstrocytomaBrain NeoplasmsDog DiseasesGliomaOligodendrogliomaAnimalsBiomarkersDogsHumansIsocitrate DehydrogenaseMagnetic Resonance ImagingMutationRetrospective StudiesBiomarkersIsocitrate Dehydrogenasebrain tumorCNS disordersmagnetic resonance imagingneuroimagingneurologyoncology-diagnosisradiology and diagnostic imaging

Identifiers

PMID37246729
PMCPMC10365042
OpenAlexW4378639923

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.